Venous Gangrene and Cancer
Author Information
Author(s): Osman Khalid A, Ahmed Mohamed H, Abdulla Samir A, Bucknall Tim E, Rogers Colin A
Primary Institution: Department of Surgery, Queen's Hospital, Burton Hospitals NHS Trust, Staffordshire, UK
Hypothesis
The presence of anticardiolipin antibodies increases the risk of venous gangrene in cancer patients.
Conclusion
Venous gangrene is rare in cancer patients but is associated with a complex pathogenesis involving hypercoagulable states and various risk factors.
Supporting Evidence
- Venous gangrene is associated with poor prognosis in cancer patients.
- Anticardiolipin antibodies double the risk of thrombo-embolic events in cancer patients.
- LMWH is suggested as a safe and effective treatment for venous thromboembolism in cancer patients.
Takeaway
Venous gangrene is a serious condition that can happen to cancer patients, and certain treatments can help prevent it.
Methodology
Review of existing literature and case studies on venous gangrene in cancer patients.
Limitations
The incidence of venous gangrene in cancer patients is not well established, and further research is needed.
Participant Demographics
Patients with solid tumors, particularly those with advanced malignancies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website